The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1275 articles
A groundbreaking BMJ study reveals GLP-1 drugs like Ozempic may reduce the risk of developing substance use disorders by 14% in diabetes patients. Among those with existing addictions, hospital admissions dropped 26%. While promising, these are associations from veteran health records—randomized trials are needed for proof.
Oprah Winfrey turned heads at Paris Fashion Week with a noticeably slimmer figure, igniting Ozempic speculation across social media. While the 72-year-old host hasn't confirmed using the drug, her recent podcast revelations about GLP-1 medications have fueled the conversation. Dive into the details of her chic appearance and the science of these popular injectables.
Doctors publicly tout GLP-1 drugs like Ozempic for weight loss, but privately warn patients may need them lifelong. A systematic review of 48 studies reveals up to 60% weight regain after stopping. Here's how to use Ozempic as a kickstart and make weight loss permanent with lifestyle changes.
While AI hype focuses on drug discovery, Eli Lilly has quietly used it to supercharge manufacturing of its blockbuster GLP-1s, Zepbound and Mounjaro. This led to record production volumes that avoided FDA shortages and fueled massive revenue growth. Here's how they did it with digital twins and defect detection tech.
A new study shows that some patients on GLP-1 drugs like Wegovy can space out injections every other week or longer and still keep weight off. Led by Dr. Mitch Biermann at Scripps Clinic, the research followed 34 patients who maintained health gains after reducing frequency. Experts say this reframes long-term obesity treatment discussions.
Deutsche Bank has reiterated its Buy rating on Eli Lilly stock, highlighting robust GLP-1 prescription growth despite recent dips. With Mounjaro and Zepbound leading, prescriptions rebounded 7% week-over-week, underscoring Lilly's dominance in the diabesity market. Discover the latest data on oral Wegovy and emerging oral GLP-1s like orforglipron.
Aspen Pharmacare Holdings Ltd. is aiming for regulatory approval of its copycat semaglutide version in Canada by September, positioning itself as a first-mover. CEO Stephen Saad shared this timeline in a recent interview, highlighting Canada's role as a benchmark for other nations. This development could enhance affordability of GLP-1 therapies like Ozempic.
Irish pharmaceutical exports hit a record €139bn in 2025, with GLP-1 weight-loss drugs from Eli Lilly and Novo Nordisk driving 20% of total goods exports. Eli Lilly's facilities in Ireland and massive US investments underscore the sector's growth. This boom promises faster access to innovative metabolic treatments for patients.
Novo Nordisk has received a second FDA untitled letter in weeks, this time targeting an Ozempic digital ad that parodies Apple's 'Get a Mac' campaign with actors Justin Long and John Hodgman. The regulator cites misleading presentations of Ozempic's indications and unsubstantiated superiority claims over other GLP-1s. Understand the concerns and what it means for patients seeking accurate information on these therapies.
